Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic MSCs for Radiation-Induced Xerostomia
NCT07431645Phase 1Completed
- Sponsor
- Institute of Oncology Ljubljana
- Start
- Apr 2023
- Primary completion
- Oct 2025
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of allogeneic bone marrow-derived mesenchymal stromal cells (ICSCYL) in radiation-induced xerostomia, sponsored by Institute of Oncology Ljubljana. Primary endpoint: Incidence of treatment-emergent adverse events at 4 months. Started Apr 2023; status: completed.
02
Drugs
allogeneic bone marrow-derived mesenchymal stromal cells (ICSCYL)
03
Conditions
radiation-induced xerostomia
Beyond the preview
Go deeper on NCT07431645.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07431645.